Literature DB >> 12654676

Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys.

Chin-Chung Lin1, Li-Tain Yeh, Trong Luu, David Lourenco, Johnson Y N Lau.   

Abstract

Absorption, pharmacokinetics, distribution, metabolism, and excretion of [(14)C]ribavirin were studied in rats (30 mg/kg of body weight) and cynomolgus monkeys (10 mg/kg) after intravenous (i.v.) and oral administration. The oral absorption and bioavailability were 83 and 59%, respectively, in rats and 87 and 55%, respectively, in monkeys. After i.v. administration, the elimination half-life (t([1/2])) was 9.9 h in rats and 130 h in monkeys and the total body clearance was 2,600 ml/h/kg in rats and 224 ml/h/kg in monkeys. The apparent volume of distribution was 11.4 liter/kg in rats and 29.4 liter/kg in monkeys. There was extensive distribution of drug-derived radioactivity into red blood cells and extensive metabolism of ribavirin in rats and a lesser degree of metabolism in monkeys. Excretion of total radioactivity in urine from rats accounted for 84% of the i.v. dose and 83% of the oral dose, whereas that from monkeys accounted for 47% of the i.v. dose and 67% of the oral dose. Several metabolites were observed in plasma and urine from both species. The amount of unchanged ribavirin in urine from both species was quite small after either i.v. or oral administration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12654676      PMCID: PMC152481          DOI: 10.1128/AAC.47.4.1395-1398.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

Review 1.  Mechanisms of action of ribavirin in antiviral therapies.

Authors:  R C Tam; J Y Lau; Z Hong
Journal:  Antivir Chem Chemother       Date:  2001-09

2.  The ribavirin analog ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis-induced serum alanine aminotransferase levels.

Authors:  R C Tam; K Ramasamy; J Bard; B Pai; C Lim; D R Averett
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

3.  The relationship between the metabolism of ribavirin and its proposed mechanism of action.

Authors:  J P Miller; L J Kigwana; D G Streeter; R K Robins; L N Simon; J Roboz
Journal:  Ann N Y Acad Sci       Date:  1977-03-04       Impact factor: 5.691

4.  Contact hypersensitivity responses following ribavirin treatment in vivo are influenced by type 1 cytokine polarization, regulation of IL-10 expression, and costimulatory signaling.

Authors:  R C Tam; C Lim; J Bard; B Pai
Journal:  J Immunol       Date:  1999-10-01       Impact factor: 5.422

5.  Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.

Authors:  R C Tam; B Pai; J Bard; C Lim; D R Averett; U T Phan; T Milovanovic
Journal:  J Hepatol       Date:  1999-03       Impact factor: 25.083

6.  The metabolism of ribavirin in erythrocytes and nucleated cells.

Authors:  T Page; J D Connor
Journal:  Int J Biochem       Date:  1990

7.  Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide.

Authors:  R W Sidwell; J H Huffman; G P Khare; L B Allen; J T Witkowski; R K Robins
Journal:  Science       Date:  1972-08-25       Impact factor: 47.728

8.  Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent.

Authors:  D G Streeter; J T Witkowski; G P Khare; R W Sidwell; R J Bauer; R K Robins; L N Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1973-04       Impact factor: 11.205

9.  Plasma disappearance, urine excretion, and tissue distribution of ribavirin in rats and rhesus monkeys.

Authors:  E A Ferrara; J S Oishi; R W Wannemacher; E L Stephen
Journal:  Antimicrob Agents Chemother       Date:  1981-06       Impact factor: 5.191

10.  Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome.

Authors:  O L Laskin; J A Longstreth; C C Hart; D Scavuzzo; C M Kalman; J D Connor; R B Roberts
Journal:  Clin Pharmacol Ther       Date:  1987-05       Impact factor: 6.875

  10 in total
  8 in total

1.  Absorption, metabolism, and excretion of [14C]viramidine in humans.

Authors:  Chin-Chung Lin; Christine Xu; Nanqun Zhu; Li-Tain Yeh
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

2.  The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1-/- mice.

Authors:  Christopher J Endres; Aaron M Moss; Rajgopal Govindarajan; Doo-Sup Choi; Jashvant D Unadkat
Journal:  J Pharmacol Exp Ther       Date:  2009-07-14       Impact factor: 4.030

3.  Disposition and metabolic profiles of [14C]viramidine and [14C]ribavirin in rat and monkey red blood cells and liver.

Authors:  Chin-Chung Lin; David Lourenco; Guifen Xu; Li-Tain Yeh
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

4.  Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys.

Authors:  Chin-Chung Lin; Kenneth Luu; David Lourenco; Li-Tain Yeh
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

5.  Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin.

Authors:  Guillaume Lingas; Kyle Rosenke; David Safronetz; Jérémie Guedj
Journal:  PLoS Comput Biol       Date:  2021-01-07       Impact factor: 4.475

6.  Precision Medicine: Determination of Ribavirin Urinary Metabolites in Relation to Drug Adverse Effects in HCV Patients.

Authors:  Ottavia Giampaoli; Fabio Sciubba; Elisa Biliotti; Mariangela Spagnoli; Riccardo Calvani; Alberta Tomassini; Giorgio Capuani; Alfredo Miccheli; Gloria Taliani
Journal:  Int J Mol Sci       Date:  2022-09-02       Impact factor: 6.208

7.  Occurrence and risk assessment of typical PPCPs and biodegradation pathway of ribavirin in wastewater treatment plants.

Authors:  Qixin Liu; Xuan Feng; Ning Chen; Fei Shen; Haichuan Zhang; Shuo Wang; Zhiya Sheng; Ji Li
Journal:  Environ Sci Ecotechnol       Date:  2022-05-03

Review 8.  Antiviral Drug Delivery System for Enhanced Bioactivity, Better Metabolism and Pharmacokinetic Characteristics.

Authors:  Ran Chen; Tingting Wang; Jie Song; Daojun Pu; Dan He; Jianjun Li; Jie Yang; Kailing Li; Cailing Zhong; Jingqing Zhang
Journal:  Int J Nanomedicine       Date:  2021-07-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.